⚠
Is this information incorrect? This profile was AI-generated from publicly available sources and may contain errors. If you are a representative of Cosmica Biosciences and believe any information on this page is inaccurate, we will promptly correct or remove it.REPORT AN ERROR
Cosmica Biosciences
↗San Francisco, USA
Cosmica Biosciences is a biotechnology company focused on precision longevity and the development of measurement and intervention tools for aging. The company leverages space biology, specifically the impact of microgravity on human cells, to understand and develop treatments for age-related diseases and neurodegeneration.
Their platform integrates multi-omic monitoring, biomarker identification, and high-throughput screening using human organoids. Key products include BeyondAge, a transcriptomic biological aging assay, and research initiatives aimed at reversing neural aging and treating conditions like Parkinson's disease.
CLASSIFICATION
SIZE & FINANCIALS
Employees:1-50
Revenue:$0.1M-$1M
Founded:2022
Ownership:private
Status:operating
FUNDING
Stage:Seed
Total Raised:$0.3M
Investors:VitaDAO
PIPELINE
Stage:Discovery
Lead Drug Stage:Preclinical
Modalities:Gene therapy, Small molecule
Active Trials:0
Trial Phases:-
FDA Approvals:0
EMA Approvals:0
CORPORATE STRUCTURE
Key Partnerships:Buck Institute for Research on Aging (Research collaboration and IP licensing)
COMPETITION
Position:Emerging
Competitors:Edifice Health, ResTORbio, Tornado Therapeutics
LEADERSHIP
Key Executives:
Abhay Saini - Director of Operations
Scientific Founders:Dr. David Furman, Chris Mason, PhD
LINKS
Website:cosmica.bio
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with Cosmica Biosciences. The information on this page was compiled using AI from publicly available sources and may be incomplete, outdated, or contain errors. We are committed to correcting inaccuracies promptly upon notice. For official information, please visit the company's website directly.